Bergenbio ASA
OSE:BGBIO
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
7
33.15
|
Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BGBIO stock under the Base Case scenario is 0.195 NOK. Compared to the current market price of 7.263 NOK, Bergenbio ASA is Overvalued by 97%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Bergenbio ASA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BGBIO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Bergenbio ASA
Balance Sheet Decomposition
Bergenbio ASA
Current Assets | 218.3m |
Cash & Short-Term Investments | 200.1m |
Receivables | 12.9m |
Other Current Assets | 5.3m |
Non-Current Assets | 220k |
PP&E | 221k |
Other Non-Current Assets | -1k |
Current Liabilities | 43.2m |
Accounts Payable | 8.6m |
Other Current Liabilities | 34.6m |
Earnings Waterfall
Bergenbio ASA
Revenue
|
521k
NOK
|
Operating Expenses
|
-162.7m
NOK
|
Operating Income
|
-162.2m
NOK
|
Other Expenses
|
6.8m
NOK
|
Net Income
|
-155.4m
NOK
|
Free Cash Flow Analysis
Bergenbio ASA
NOK | |
Free Cash Flow | NOK |
BerGenBio reported progress in its study of bemcentinib for non-small cell lung cancer, targeting STK11 mutations. With a consistent quarterly burn rate of NOK 40 million, the company anticipates cash to last until mid-2025, with a current cash position of NOK 200 million. Positive recommendations have been received for the safety of two dose levels moving into the Phase IIa trial, aimed at enrolling 40 patients. The firm forecasts significant improvements in progression-free survival from 5 to over 8 months and overall survival up to 14-15 months. Updates are expected later this year and early 2025, keeping investor interest high.
What is Earnings Call?
BGBIO Profitability Score
Profitability Due Diligence
Bergenbio ASA's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Bergenbio ASA's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
BGBIO Solvency Score
Solvency Due Diligence
Bergenbio ASA's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Score
Bergenbio ASA's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BGBIO Price Targets Summary
Bergenbio ASA
According to Wall Street analysts, the average 1-year price target for BGBIO is 20.4 NOK with a low forecast of 5.05 NOK and a high forecast of 39.9 NOK.
Dividends
Current shareholder yield for BGBIO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.
Contact
IPO
Employees
Officers
The intrinsic value of one BGBIO stock under the Base Case scenario is 0.195 NOK.
Compared to the current market price of 7.263 NOK, Bergenbio ASA is Overvalued by 97%.